Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485326 | 0.83 | OPRL1 (0.61) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL28548988 | 0.80 | OPRL1 (0.71) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL13864819 | 0.78 | OPRL1 (0.55) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL11370652 | 0.78 | CYP2D6 (0.60) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL26087024 | 0.78 | TSHR (0.44) | OPRL1POLBCYP3A4SIGMAR1ALDH1A1 | |
| SCHEMBL4782995 | 0.78 | OPRL1 (0.54) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL653329 | 0.77 | OPRL1 (0.67) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL8804780 | 0.77 | OPRL1 (0.67) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL2953304 | 0.77 | CYP2D6 (0.55) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL2918565 | 0.77 | SIGMAR1 (0.65) | OPRL1POLBCYP3A4HSD17B10CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | OPRL1 58/4885POLB 4490/4885CYP3A4 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.